ClinicalTrials.Veeva

Menu
C

Cumberland Valley Retina Consultants (CVRC) | Hagerstown, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
EYE103

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 3 total trials

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

Trial sponsors

E
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems